APOTEX CORP.
🇺🇸United States
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
161
FDA:161
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 17
- Next
Clinical Trials
No trials found
News
Apotex Launches First Generic Nilotinib in US with 180-Day Market Exclusivity
Apotex Corp. announced the launch of nilotinib capsules, the first generic version of Tasigna® in the United States, with 180 days of market exclusivity.